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Prostate cancer (PC) is one of the most common malignancies in
the W estern hemisphere. In Germany, PC is the third most
common cause of male cancer mortality (Hölzel et al, 1996).
Androgens (testosterone and  5a-dihydrotestosterone) are essential
for development, growth, di f ferentiation and maintenance of o rgan
structure of the prostate. Physiologicall y, androgen deprivation
leads to apoptosis (Isaacs et al, 1994). The action of the androgens
is mediated by the intracellular androgen receptor (AR) molecule
( Trapman and Brinkmann, 1996). Initiall y, the growth of prostatic
carcinomas is androgen-dependent in most cases. In locally
advanced and/or metastasized PC, where prostatectomy is not
curative, androgen deprivation therapy (ADT) performed either by
castration or by other forms of endocrine manipulation (anti-
androgens, luteinizing-hormone-releasing hormone (LH-RH)
analogues) has been used for palliative therapy for more than 5
decades (Huggins and Hodges, 1941). Howeve r, nearly all cases
become refractory to androgens within a few years. The molecular
changes underlying androgen-independence and tumour progres-
sion are as yet widely unknown.
Unlike the oestrogen and progesterone receptor status in breast
cancer, the expression of the AR molecule in PC does not correlate
with clinical response to ADT (Miyamoto et al, 1993;  Trapman
and Brinkmann, 1996). This finding can be explained partly by
mutations (Klocker et al, 1994; Peterziel et al, 1995;  Taplin et al,
1995; Suzuki et al, 1996) or amplifications of the AR gene after
ADT ( V isakorpi et al, 1995). Howeve r, these aberrations are
not present uniformly in hormone-independent carcinomas.
Consequentl y, other mechanisms must be involved in the evolu-
tion of androgen-independent tumour progression as well.
In analogy to the physiological situation, the analysis of factors
regulating cell proliferation and apoptosis may be important in this
context, not only for scientific reasons, but also from a clinical
point of vie w .  To the best of our knowledge, howeve r, studies have
been missing up to now that investigate changes of proliferation-
and programmed cell death (PCD)-associated factors in PC after
ADT over a longer period of time. In order to avoid a therapy-
related bias, the cases were classified into groups with either
conventional ADT (by orchiectomy and/or drugs) or ADT and
Proliferation- and apoptosis-associated factors in
advanced prostatic carcinomas before and after
androgen deprivation therapy: prognostic significance
of p21/WAF1/CIP1 expression
GB Baretton1, U Klenk1, J Diebold1, N Schmeller2 and U Löhrs1
1Institute of Pathology, Ludwig-Maximilians-University, Thalkirchnerstr. 36, D-80337 Munich, Germany, and 2Department of Urology, Klinikum Grobhadern,
Ludwig-Maximilians-University, Marchioninistr. 15, D-81377 Munich, Germany
SummaryThe molecular mechanisms leading to androgen-independent growth in prostate cancer (PC) are poorly understood. Androgen
deprivation therapy (ADT) results physiologically in a decrease in proliferation and an increase in programmed cell death (PCD)/apoptosis.
The aim of our study was to get more insight into these processes in prostatic carcinomas before and after ADT. For this purpose,
immunohistologic staining for the androgen receptor (AR) molecule, the Ki-67 antigen, the bcl-2 oncoprotein, the p53 protein and its
physiologic effector, p21/WAF1, was performed on archival material. PCD was visualized by enzymatic detection of DNA fragmentation.
Specimens from 69 PC patients after ADT were studied in correlation to histopathology and prognosis. In 42 cases, corresponding tumour
tissue from the untreated primary tumours could be analysed comparatively. Before ADT, histologic grade was associated with Ki-67 index
(P < 0.0001, Spearman correlation) and PCD rate (P < 0.05, Spearman correlation). Ki-67 index correlated with PCD rate (P < 0.05,
Spearman correlation) and p21/WAF1 expression (P < 0.01, Fisher’s exact test). p21/WAF1 expression was the only statistically significant
prognostic factor for shorter survival (P < 0.002, log-rank test). All p21/WAF1-positive cases showed high Ki-67 index and high histologic
grade. After ADT, loss of AR expression was associated with high Ki-67 index, whereas histologic signs of regression correlated negatively
with Ki-67 index (P < 0.001, Pearson c2 test). p21/WAF1 expression increased significantly (P < 0.02, McNemar test) and correlated with p53
accumulation (P < 0.0001, Pearson c2 test). Most significant prognostic parameter after conventional ADT was high-rate p21/WAF1
expression (> 50% of tumour cells; P < 0.00001, log-rank test). This study demonstrates that p21/WAF1 overexpression before and after ADT
characterizes a subgroup of advanced PC with paradoxically high proliferation rate and significantly worse clinical outcome. This finding might
be clinically useful for planning therapy in these patients.
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additional therapy regimens (radiation or chemotherapy). The
proliferation-associated Ki-67 antigen, the p53 protein and its
physiologic effector, the p21/WAF1 protein, both known to be
involved in the regulation of cell cycle and PCD/apoptosis, the
apoptosis-inhibiting bcl2-oncoprotein, and the AR molecule were
determined immunohistochemically. Furthermore, the PCD rate
was visualized in situ by enzymatic detection of DNA fragmenta-
tion and quantified. The prognostic impact of these parameters
was tested before and after long-standing ADT.
MATERIALS AND METHODS
Materials and patients
Formalin-fixed and paraffin-embedded tumour tissue from a total
of 69 patients with locally advanced or metastasized primary
prostatic carcinomas was studied after ADT with and without
additional therapy regimens. The mean duration of ADT was 40.6
months ± 39.3 (median 30 months; range 0.4–169.4 months). The
mean age of the patients at time of diagnosis was 67.5 ± 8.8 years
(range 46–83 years).
Tumours were graded according to Gleason and Mellinger
(Gleason, 1966; Gleason and Mellinger, 1974). For statistical
calculations, a grade compression was performed with a cut-point
between scores 6 and 7, i.e. low-grade vs high-grade (Gleason,
1992; Table 1). In 42 cases, paired specimens from both the
untreated primary tumour and the recurrence after ADT were
available (mean duration of ADT 26.8 ± 29.1 months; median 16.5
months, range 0.4–105.8 months; Table 2).
In 26 of these cases, only a conventional ADT was performed
(‘core-group’) either by orchiectomy (OE; n = 8), or by OE and
drugs (n = 11) or only by drugs (n = 7). For the ADT by drugs
flutamide, fosfestrol, or cyproteronacetate were used primarily;
later the patients were also treated with leuprorelinacetate, buse-
relinacetate, or goserelinacetate.
In the remaining 16 cases, an additional radiation (n = 2) or
chemotherapy (n = 9), or a form of therapy that was not thoroughly
documented (n = 5), was applicated in the further course. These
cases were studied separately in order to avoid a therapy-related
bias. For chemotherapy estramustin, 4¢-epirubicin, or cisplatin
were used.
In addition, tumour tissue from 27 patients after ADT was
studied without paired material from the primary tumour. Fourteen
of these patients were pretreated only by conventional ADT (OE:
n = 4; OE + drugs: n = 7; only drugs: n = 3). Thus, tumour tissue
from a total of 40 patients after conventional ADT alone was
available. In the remaining 13 cases, an additional radiation
(n = 3), chemotherapy (n = 8), or therapy not further specified
(n = 2) had been performed.
Table 1 Gleason scores of the prostatic carcinomas after ADT
Gleason score All PC after ADT PC after ADT pretreated only
by conventional ADT
4 2 (1a) Low-grade (n = 5) 2 (1a) Low-grade (n = 4)
50 0
6 3 (1a)2
71 1
8 9 (1b) High-grade (n = 64) 6 (1b) High-grade (n = 36)
9 26 (1c) 14 (1c)
10 28 (1a, 1b, 1c) 15 (1a, 1c)
Total 69 40
Gleason scores and material (if not mentioned: transurethral resection/TUR; atransrectal punch biopsy, bsubtotal
transabdominal resection, cpulmonary metastasis) of the prostatic carcinomas after ADT discriminated according to
subsequent therapy; all tumours under study (n = 69; median 9, mean 8.97 ± 1.3) and cases pretreated only by conventional
androgen deprivation (castration and/or drugs; n = 40; median 9, mean 8.8 ± 1.5). For statistical calculations a grade
compression was performed with a cut-point between scores 6 and 7 (low-grade vs high-grade).
Table 2 Gleason scores of the untreated primary prostatic carcinomas
Gleason score All PC before treatment PC treated only by conventional ADT
in the further course
4 3 (2a) Low-grade 1 (1a) Low-grade
5 1 (1a)( n = 11) 1 (1a)( n = 9)
6 7 (4a, 2b) 7 (4a, 2b)
7 12 (5a) 10 (5a)
8 8 (5a) High-grade 3 (3a) High-grade
9 9 (1a)( n = 31) 3 (n = 17)
10 2 (1a)1
Total 42 26
Gleason scores and material (if not mentioned = transurethral resection/TUR; atransrectal punch biopsy, bsubtotal
transabdominal resection) of the untreated primary prostatic carcinomas discriminated by subsequent therapy; all tumours
under study (n = 42; median 7, mean 7.3 ± 1.5) and cases treated only by conventional ADT in the further course (castration
and/or drugs; n = 26; median 7, mean 7.0 ± 1.3). For statistical calculations a grade compression was performed with a cut-
point between scores 6 and 7 (low-grade vs high-grade).548 GB Baretton et al
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The material comprised 83 transurethral resections (TUR), 22
transrectal punch biopsies, four subtotal transabdominal prostatic
resections, and two pulmonary metastasis (Tables 1 and 2). All
samples were routinely fixed in 4% buffered formalin and
embedded in paraffin (total of 111 paraffin blocks).
In the tumour tissue after ADT nuclear size reduction, loss of
recognizable nucleoli, chromatin condensation, nuclear pyknosis
and vacuolization of the cytoplasm of the tumour cells were
recorded as histopathological signs of regression (Civantos et al,
1995). If these features were lacking, the case was classified
histopathologically as regression-negative.
In 66 cases, clinical follow-up data were available, including all
patients with paired tumour samples before and after ADT (mean
time of observation: 59.5 ± 48.9 months; median 47 months;
range: 1–215 months). Twenty-seven of 66 patients died.
Methods
Immunohistochemistry
Sections (3–4 mm thick) were cut from the paraffin blocks and
mounted on Super-Frost/Plus microscope slides (Menzel,
Germany) and dried for 24 h at 56°C. After deparaffinization,
rehydration and washing in phosphate-buffered saline (PBS) the
slides were placed in a Coplin jar that was filled with 10 mM citrate
buffer (pH 6.0). The jar was heated in an autoclave (Webeco,
Germany) at 120°C (1.2 bar) for 20 min (Piffko et al, 1995). The
jar was then allowed to cool at room temperature. After three
washings in PBS the slides were incubated with 75 ml of the
primary monoclonal antibodies prediluted in 1% bovine serum
albumin (Sigma, Deisenhofen, Germany) in PBS for 20 h at 6°C in
a wet chamber (Table 3).
The reactions were visualized by an amplified biotin–strepta-
vidin method (Super Sensitive Multilink Immunodetection
SystemTM; BioGenex, San Ramon, CA, USA). For this purpose,
after washing in PBS, the sections were incubated for 30 min
(21°C, wet chamber) with the biotinylated anti-mouse antibody
(Super Sensitiv Multilink, HK 340-9K; BioGenex, USA). After
washing again in PBS an incubation with alkaline–phosphatase
conjugated streptavidin (Super Sensitiv Label, HK 331-9K;
BioGenex, USA) was performed (30 min, 21°C, wet chamber).
Fast red–naphthole AS-MX phosphate (F-4523; Sigma, Germany)
served as chromogene. Finally, the slides were counterstained with
haematoxylin and mounted in Aquatex (Merck, Germany).
Analysis of the immunohistochemical reactions
Ki-67
According to the immunoreaction in 1000 tumour cells/tumour the
mean percentage of nuclei with a positive immunoreaction was
determined (= Ki-67 index). A Ki-67 index was classified as high
if it was ³ 14.7%, which represented the median value in the
42 primary PC before ADT.
AR
A tumour was classified as positive for AR molecule expression if
a clear positive nuclear reaction was present in > 95% of the
tumour cells. Cases with no, or only single, positive cells (< 5%)
were regarded as negative.
p53 and p21/WAF
The results of the p53 and p21/WAF1 immunoreaction were
recorded as positive if a distinct nuclear staining was seen in at
least 20% of the tumour cells in a microscope field at 100-fold
magnification (Zeiss Axioskop microscope: objective 10/0.30,
ocular 10´/20; Zeiss, Germany). A further subclassification was
performed in cases with p21/WAF1 immunoreactivity in > 50% of
all tumour cells; those cases were classified as high-rate positive.
Cases with no, or only single, positive cells were regarded as nega-
tive.
This classification was used because there is increasing
evidence that p53 immunoreactivity in only a few tumour cells, or
even normal cells, does not correlate with a TP53 mutation, but
represents overexpression of wild-type p53 due to physiologic
DNA repair. Accordingly, the effector of the wild-type p53-
protein, i.e. p21/WAF1, can physiologically show a positive
reaction in single cells.
bcl-2
The immunohistochemical results for bcl-2 were recorded as posi-
tive if the tumour cells showed an unequivocally strong cytoplas-
matic immunoreaction in at least 20% of the tumour cells in a
microscope field at 100-fold magnification (see above). Cases
with only equivocally faint staining were regarded as negative.
Positive-reacting lymphocytes and basal cells in preserved non-
neoplastic prostatic glands served as internal control.
Detection of apoptotic cells in paraffin sections
DNA fragments of apoptotic cells were visualized by an enzymatic
reaction (Gavrieli et al, 1992; Ansari et al, 1993). After dewaxing
in xylene, rehydration, washing in PBS and pretreatment of the
sections with proteinase K (Sigma, Germany; 40 mg ml–1 in PBS,
21°C, 45 min), the endogenous peroxidase activity was blocked in
3% hydrogen peroxide for 5 min. Subsequently, the terminal trans-
ferase reaction was performed using the ApopTagTM kit (In Situ
Apoptosis Detection Kit, Peroxidase, S 7100-Kit; ONCOR,
Gaithersburg, MD, USA). DAB (3,3’-diaminobenzidintetra-
hydrochloride; D-51905; Sigma, Germany) served as chromogen
(one tablet in 15 ml PBS). After 5 min of incubation with DAB,
Table 3 List of primary antibodies used for immunohistochemistry
Antibody Clone Company Dilutiona
Ki-67 MIB 1 Dianova, Hamburg, Germany 1:1000
p53 DO 1 Dianova, Hamburg, Germany 1:100
p21/WAF1 clone EA10 Dianova, Hamburg, Germany 1:100
bcl-2 clone 124 DAKO, Hamburg, Germany 1:750
Androgen receptor F 39.4.1 BioGenex, San Ramon, CA, USA 1:10
Primary monoclonal antibodies used for the immunohistochemical reactions and dilutions (*in 1% bovine
serum albumin (Sigma, Germany) in PBS).Prognostic significance of p21/WAF1 in advanced prostate cancer 549
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the slides were washed in running tap water for 10 min and in
double-distilled water (DDW) for 5 min. Afterwards, the slides
were counterstained with methyl green (HK 141-7K; BioGenex,
USA) for 10 min under a cover-glass at 21°C, washed again in
DDW and mounted with Aquatex (Merck, Germany).
As positive controls, preserved non-neoplastic prostatic glands
within the slides from primary tumours, or lymphocytes in lymph
follicles, were used. Since the enzymatic reaction described labels,
both apoptotic cells and areas of necrosis, the only labelled cells
that were regarded as positive were those that showed additional
characteristics of apoptosis, e.g. isolated localization within an
intact cell complex without an inflammatory reaction. At least
10 000 tumour cells per case were evaluated. The results were
expressed as positive cells per 1000 tumour cells.
As 2.5% represented the median value of apoptotic cells in the
42 primary tumours before ADT, a PCD index < 2.5% was con-
sidered low, and a PCD index > 2.5% high.
Statistical analyses
Mean parameter values ± standard error of the mean (S.E.M.) were
statistically compared by Spearman correlation, c2 analysis, Fisher’s
exact test, Wilcoxon’s signed rank test, and the McNemar test
(Hollander and Wolfe, 1973; Breslow and Day, 1980). Survival
analyses were performed by Kaplan–Meier curves and the log-rank
test using the SPSS statistical software (SPSS Inc., Chicago, IL,
USA). P < 0.05 was regarded as statistically significant.
RESULTS
Prostatic carcinomas before ADT
AR molecule
All primary PC showed a nuclear expression of the AR molecule
before ADT.
bcl-2
Twenty of 42 PC before ADT (48%) exhibited a positive cytoplas-
matic immunohistochemical reaction for bcl-2. In the subgroup
of 26 carcinomas treated later only by conventional ADT, 15 cases
were bcl-2-positive (58%). The pattern of immunostaining was
not uniform within the tumours; clusters of cells that reacted
positively alternated with only faint staining areas within an
individual carcinoma without correlation to histologic grade of the
tumours or the other parameters under study. A positive cytoplas-
matic bcl-2 reaction was also present in the basal cells in non-
neoplastic glands in the adjacent prostate tissue corresponding
with the physiologic proliferative zone and in reactive lympho-
cytes/lymphoid follicles infiltrating the prostate.
p53
Eleven of 42 untreated carcinomas (26%) were immunohisto-
chemically p53-positive (including six of the 26 cases (23%) with
subsequent conventional ADT without additional radiation or
chemotherapy), whereas in the remaining tumours no nuclear p53
accumulation could be observed. In all positive carcinomas,
however, parts of the neoplasms remained negative. All p53-posi-
tive carcinomas were histologically high-grade tumours; however,
the correlation between p53 and histological grade was not statisti-
cally significant. Furthermore, no correlations between p53 accu-
mulation and the other parameters under study could be found.
The preserved non-neoplastic prostatic tissue showed no p53
immunoreactivity.
p21/WAF1
Seven of 42 PC before ADT (17%) showed a positive nuclear
immunoreaction for p21/WAF1. In this group, p21/WAF1 expres-
sion was correlated positively with Ki-67 index (P < 0.01, Fisher’s
exact test). In the subgroup of 26 patients with conventional ADT
in the later course, four tumors were p21/WAF1-positive (15%).
The reaction pattern was heterogeneous in the tumours demon-
strating positive foci of tumour cells alternating with negative
areas (Figure 1). The distribution of cases with focal and high-rate
p21/WAF1 immunoreactivity is shown in Table 4. No statistically
significant correlations could be established between p21/WAF1
immunoreactivity, histologic tumour grade or other parameters
under study. p21/WAF1-positive tumours were histologically
mostly high-grade carcinomas, showed high Ki-67 and PCD
index, and were bcl-2-positive; however, these associations were
statistically not significant. In the non-neoplastic prostate tissue,
very few epithelial cells showed an occasional positive p21/WAF1
immunoreactivity (< 1%) in all cases.
Figure 1 Focally positive immunohistological reaction for p21/WAF1 (> 20%
of tumour cell nuclei) in a prostatic adenocarcinoma (Gleason score 7) before
androgen deprivation therapy (monoclonal antibody clone EA 10,
haematoxylin, original magnification 200´)
Table 4 p21/WAF1 immunoreactivity in prostatic carcinomas before and
after ADT
p21/WAF1 immunoreactivity
Focal positivitya High-rate Total pos.
positivityb
n (%) n (%) n (%)
Before ADT
All cases (n = 42) 6 (14) 1 (2) 7 (17)
‘Core-group’
(n = 26) 3 (12) 1 (4) 4 (15)
After ADT
All cases (n = 69) 21 (30) 10 (15) 31 (45)
Cases with paired 12 (29) 7 (17) 19 (45)
samples (n = 42)
‘Core-group’ 6 (23) 6 (23) 12 (46)
(n = 26)
p21/WAF1 immunoreactivity in prostatic carcinomas before and after ADT.
Cases with afocal p21/WAF1 expression (> 20% of tumour cells in one
microscope field, 100´), bhigh-rate p21/WAF1 immunoreactivity (> 50% of all
tumour cells), and the total number of p21/WAF1-positive cases in the
different subgroups under study.550 GB Baretton et al
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Ki-67
The mean value of the Ki-67 index was 17.4 ±12.1% in the
untreated PC. According to the defined classes of proliferation,
the cases with low and high Ki-67 were distributed equally (50%).
In the core group, 62% of the cases (n= 16) showed a low, and
38% (n= 10) a high, Ki-67 index respectively. Statistically signi-
ficant positive correlations could be established between Ki-67
index and histologic grade (P< 0.0001, Spearman correlation) as
well as between Ki-67 index and PCD index (P< 0.05, Spearman
correlation).
poptosis
In the 42 tumours before ADT, the mean PCD index was 2.96 ±
2.6%. The PCD index was graded as low (< 2.5%) in 22 cases
(52%) and as high in 20 carcinomas (48%; Figure 2). From the 26
prostate cancer patients treated subsequently only by conventional
ADT, 17 tumours (65%) showed a low PCD index and nine
carcinomas (35%) exhibited a high PCD index. The PCD index
correlated statistically significantly with tumour grade (P< 0.05,
Spearman correlation) and, as mentioned above, with Ki-67 index
(P< 0.05, Spearman correlation). Moreover, a positive correlation
between PCD index and patients, age could be found (P< 0.02). In
nearly all cases, scarce apoptotic cells were also detected by
terminal transferase reaction in the secretory epithelial cells of
non-neoplastic prostatic glands.
Prognostic significance
The only parameter with statistically significant prognostic impact
on prognosis before ADT was the p21/WAF1 expression of the
tumour cells. Patients with p21/WAF1-positive carcinomas
showed a statistically significant shorter survival time than those
with p21/WAF1-negative tumours (P< 0.0002, log-rank test, in all
untreated prostatic carcinomas, Figure 3A; P< 0.00001, log-rank
test, in the ‘core-group’ treated only with conventional ADT,
Figure 3B).
Prostatic carcinomas after ADT
Histologic grade and signs of tumour regression
In the cases where paired tumour samples before and after ADT
were available, the Gleason score increased significantly after
therapy (P< 0.001, Wilcoxon’s signed rank test).
From the total of 69 PC after ADT, 24 carcinomas (35%)
showed histologic signs of tumour regression. In the subgroup
treated only with conventional ADT, 18 of 40 cases (45%) demon-
strated histologic changes that could be related to the therapy.
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Figure 2Cribriform prostatic carcinoma (Gleason score 8) before androgen
deprivation therapy with high PCD-/apoptotic rate (brown nuclei; PCD-index
5%; terminal transferase reaction, methyl green, original magnification 500´)
Figure 3Kaplan–Meier survival curves for patients with advanced prostatic carcinomas before androgen deprivation therapy. Statistically shorter survival for
patients with p21/WAF1 expression of the tumour cells (> 20% in a microscope field at 100-fold magnification) in the untreated primary tumours. (A) In all
patients with prostatic carcinomas under study (n = 42; P < 0.002; log-rank test). (B) In the subgroup treated by conventional ADT only in the further course
(n = 26; P < 0.00001; log-rank test)Prognostic significance of p21/WAF1 in advanced prostate cancer 551
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Independently, whether only a conventional ADT or an additional
radiation or chemotherapy had been performed, in all of these
cases, the histologic signs of regression were only slight and could
be observed only in a part of the tumour tissue.
AR molecule
After ADT, 61 PC (88%) expressed the AR molecule. After
pretreatment with conventional ADT only, 36 of 40 carcinomas
(90%) were AR-positive, including all of the 26 cases in which
also paired tumour tissue before ADT had also been analysed. The
remaining cases showed no immunoreactivity or a positive reac-
tion only in a few cells (< 5%). The loss of the AR molecule was
associated with high-rate p21/WAF1 (P < 0.02, Fisher’s exact test)
and high-rate bcl-2 (P < 0.04, Fisher’s exact test) and with a
tendency to high Ki-67 index.
bcl-2
In 42 of the carcinomas after ADT (61%), a positive cytoplasmatic
immunoreactivity for bcl-2 could be found. After conventional
ADT, 58% of the tumours showed bcl-2 positivity. Thus, a trend
towards a higher rate of bcl-2 expression after ADT could be
registered.
p53
In 26 PC (38%), a nuclear p53 accumulation could be observed. In
the ADT subgroup without additional therapeutic regimens, 12 of
40 tumours (30%) reacted p53 positively; in the 26 core-group
cases with paired tumour samples this rate was 39%. In compar-
ison with the results before ADT the rate of aberrant immunohisto-
chemical p53 expression increased insignificantly. After ADT,
p53 accumulation and p21/WAF1 expression were correlated
statistically significantly (P < 0.0001, Pearson c2 test).
A B
Figure 4 (A) Immunohistological high-rate nuclear expression of p21/WAF1 (> 50% of tumour cell nuclei) in a poorly differentiated prostatic carcinoma
(Gleason score 10) after androgen deprivation therapy (monoclonal antibody clone EA 10, haematoxylin, original magnification 250´). (B) Serial section of the
same tumour showing a high Ki-67 labelling index (40%) in the same area (monoclonal antibody MIB1, haematoxylin, original magnification 200´)
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Figure 5 Kaplan–Meier survival curves for patients with advanced prostatic carcinomas after androgen deprivation therapy. Statistically shorter survival for
patients with high-rate p21/WAF1 expression of the tumour cells (> 50% of all tumour cells) in the recurrences. (A) In all patients with prostatic carcinomas
under study (n = 66; P < 0.006; log-rank test). (B) In the subgroup pretreated by conventional ADT only in the further course (n = 40; P < 0.00001; log-rank test)552 GB Baretton et al
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p21/WAF1
Thirty-one PC analysed after ADT (45%) showed a positive
nuclear reaction for p21/WAF1 (Figure 4A). The distribution of
cases with focal and high-rate p21/WAF1 immunoreactivity is
shown in Table 4. In comparison to the status before ADT, the rate
of p21/WAF1 overexpression increased significantly (P < 0.004,
McNemar test). In the paired tumour samples after conventional
ADT only, 12 of 26 prostatic carcinomas reacted p21/WAF1
positively (46%; P < 0.02, McNemar test). As mentioned above,
p21/WAF1 expression correlated with p53 accumulation
(P < 0.0001, Pearson c2 test), as well as with Ki-67 index
(P < 0.01, Pearson c2 test; Figure 4B).
Ki-67
After ADT, the mean value of the Ki-67 index was 26.3 ± 18.5% in
the PC. The Ki-67 index was classified as low in 25 cases (36%),
and as high in 44 cases (64%). In the 40 patients treated only with
conventional ADT, these rates were 38% and 62% respectively. In
the ‘core-group’, the distribution of tumours was 46% low and
54% high Ki-67 index. A significant increase towards higher
Ki-67 index was shown in paired sample analysis (P < 0.01,
Wilcoxon’s signed rank test). The Ki-67 index was statistically
significantly correlated with grading (P < 0.001, Spearman corre-
lation) and PCD rate (P < 0.05, Spearman correlation).
Furthermore, in tumours with histologic signs of regression, the
rate of cases with low Ki-67 index was statistically significantly
higher (67%) than in the carcinomas without tumour regression
(14%; P < 0.01, Pearson c2 test).
Apoptosis
The mean value of the PCD index in the 69 prostate carcinomas
after ADT was 3.8 ± 3.6%. According to the limits mentioned
above, the PCD index was classified as low in 35 cases (51%)
and high in 34 cases (49%). In the subgroup treated only with
conventional ADT, the cases with low and high PCD index were
distributed into 60% low and 40% high PCD index. Thus, in
comparison with the status before ADT, a slight decrease of cases
with high PCD index could be found. PCD index correlated with
grading (P < 0.002, Spearman correlation) and with Ki-67 index
(P < 0.05, Spearman correlation).
Prognostic significance
In the total of 66 patients with all forms of treatment and clinical
follow-up data available, patients whose tumours showed high-
rate p21/WAF1 had a significantly shorter survival time than the
others (P < 0.006, log-rank test; Figure 5A). This result became
even more evident in the subgroup treated by conventional ADT
only (n = 40; P < 0.00001, log-rank test; Figure 5B). Moreover, in
the ‘core-group’ pretreated with conventional ADT only, the Ki-67
index and the PCD rate were statistically significant prognostic
parameters as well (Table 5).
DISCUSSION
The molecular mechanisms underlying androgen-independent
growth in PC after long standing ADT are still poorly understood.
Elucidation of these processes might lead to improvement of
existing endocrine therapeutic regimens or to the development of
new forms of therapy (Trapman and Brinkmann, 1996).
In the present investigation, we analysed immunohistochemi-
cally several factors known to be involved in the regulation of
proliferation and PCD/apoptosis. By comparing the results from
both the primary untreated PC and the recurrences after a longer
period of ADT from the same patients, we hoped to gain a better
understanding of these pathways in PC tumour cells. Since in
several cases other therapy regimens were performed in addition to
conventional ADT, the collective was subclassified into groups
with either conventional ADT alone or with ADT and additional
chemotherapy or radiation to avoid therapy-related influences on
the results. On the one hand, the discrepancies between these
groups observed in our study concerning the correlations and/or
the prognostic impact of the analysed parameters support the
necessity of a stratification of the patients with advanced prostate
cancer according to the applied therapy regimen (Table 5). On the
Table 5 Expression patterns of proliferation-/apoptosis-regulating factors, proliferative activity (Ki-67 index), and apoptosis/PCD rate in advanced prostatic
carcinomas before and after ADT and prognostic significance
Parameter PC PC
‘Core-group’ All tumours
(= paired specimens; n = 26)
Before Progn. After Progn. All PC Progn. All PC Progn. PC after Progn.
ADT sign. ADT sign. before sign. after ADT sign. ADT sign.
only ADT (n = 42) +/– (n = 66) only (n = 40)
(n = 42) additional (n = 40)
therapy
(n = 69)
AR expression 100% – 92% – 100% – 88% – 90% –
bcl-2 pos. 58% – 58% – 48% – 61% – 58% –
p53 pos. 23% – 39% – 26% – 38% – 30% –
p21/WAF1 pos. 15% P < 0.00001 46%a P < 0.002 17% P < 0.0002 45%  P < 0.006b 18% P < 0.00001b
Ki-67 index high 38% – 54% P < 0.04 50% – 64% – 63% –
PCD rate high 35% – 42% P < 0.03 48% – 49% – 40% –
Expression patterns of proliferation-/apoptosis- regulating factors, proliferative activity (Ki-67 index), and apoptosis/PCD rate in advanced prostatic carcinomas
before and after ADT and prognostic (progn. significance (sign.) of the parameters (log-rank test). Left: Cases with paired specimens from both the untreated
primary tumour and the recurrence after conventional ADT only; astatistically significant increase after ADT (P < 0.02, McNemar test). Right: All cases under
study before and after ADT with and without additional chemotherapy or radiation; bhigh rate p21/WAF1-overexpression only.other hand, these findings may explain differences between the
results of our study and other investigations published in the
literature, where no stratification was performed.
In accordance with the majority of reports in the literature, the
immunohistological AR expression was preserved in all tumours
of our series before ADT and did not correlate with clinical and
histopathologic features (Trapman and Brinkmann, 1996). After
ADT, loss of the AR molecule could be found in less than 10% of
cases. The observed association between AR loss and high Ki-67
index suggests that the AR-regulated growth control is overruled
in this subset of cases by other factors, e.g. activation of ‘classical’
oncogenes and/or inactivation of tumour suppressor genes. This
hypothesis is further supported by the observation that the Ki-67
index (and the PCD rate) were prognostically relevant for survival
in the subgroup after conventional ADT.
Furthermore, our data show that the physiologic regulation of
cell proliferation and apoptosis are obviously defective already
before ADT in the majority of advanced PC. Before and after ADT
the PCD rate was associated only with tumour grade and prolifera-
tive activity assessed by the Ki-67 index. No correlation could be
observed between PCD rate and the PCD-inhibiting bcl-2 onco-
protein expression (Korsmeyer, 1992b), supporting the view that
regulation of apoptosis is complex and bcl-2 is not the only factor
involved in this process (Krajewska et al, 1996). For example,
apoptosis may also be initiated by incompatible or conflicting
growth signals (Stewart, 1994), e.g. by c-myc, or by the activation
of a cyclin-dependent kinase at an inappropriate time during the
cell cycle (Evan et al, 1992). In agreement with earlier reports,
the rate of tumours expressing bcl-2 was higher after ADT
(McDonnell et al, 1992; Colombel et al, 1993; Westin et al, 1995),
although the increase was not statistically significant in our cases.
In contrast to other studies, no correlations between bcl-2 over-
expression and PCD rate, p53 accumulation, or clinical outcome
could be observed before and after ADT. In these investigations,
however, either locally confined, i.e. resectable prostatic carci-
nomas (Bubendorf et al, 1996), or short-term changes after ADT
were studied (McDonnell et al, 1992; Westin et al, 1995).
The  TP53 tumour suppressor gene is the most commonly
mutated gene in human cancers (Levine et al, 1991). The p53
protein plays a central role in the regulation of proliferation and
PCD. Its main physiologic function is controlling the integrity of
the DNA (Lane, 1992). If DNA damage is present the cell cycle
will be stopped in the G1 phase mediated by the p53 effector
protein p21/WAF1, and DNA repair is induced. If the damage is
irreparable, apoptotic cell death is induced. Thus, inactivation of
p53 is able to block apoptotic cell death (Korsmeyer, 1992a). As
functionally relevant mutations of the TP53 gene mostly result in
an abnormal stabilization of the mutated protein, its accumulation
can be visualized by immunohistochemistry, whereas the wild-
type p53 escapes detection due to the short half-life time. In PC,
p53 immunohistology was proven to correlate well with TP53
gene mutations (Wertz et al, 1996). Nonetheless, TP53 mutations
seem to be a late event in PC progression and are identified mainly
in poorly differentiated and metastatic tumours, indicating an asso-
ciation with poor prognosis (Visakorpi et al, 1992; Bookstein et al,
1993; Navone et al, 1993; Eastham et al, 1995; Kubota et al, 1995;
Shurbaji et al, 1995) The rates of approximately 30% and 40% of
p53 positivity in advanced PC before and after ADT, respectively,
are within the range of results for abnormal p53 accumulation
published in the literature. In our series, however, no statistically
significant correlations between p53 accumulation and clinico-
pathological features or prognosis could be established.
Obviously, the main result of our study was that overexpression
of the p21/WAF1 protein, the effector of the wild-type p53 protein,
was statistically significantly correlated with a shorter survival
time of the patients (Figures 3 and 5). As p21/WAF1 is physiolog-
ically a potent inhibitor of cyclin-dependent kinases (CDK) and
can be regarded as a negative regulator of the cell cycle inducing
either p53-mediated G1 arrest or apoptosis, this finding was unex-
pected (El-Deiry et al, 1994; Li et al, 1994; Polyak et al, 1997).
Accordingly, loss of p21/WAF1 expression was described mainly
in more aggressive tumour variants or advanced tumour stage
(Ellis et al, 1997; Gomyo et al, 1997; Harada et al, 1997;
Maelandsmo et al, 1997; Wang et al, 1997).
However, no statistically significant correlation could be found
between p53 accumulation and p21/WAF1 expression before ADT
in our study. This is in agreement with the observation that
p21/WAF1 can be activated by a p53-independent pathway as well
(Michieli et al, 1994). After ADT, the rate of both p53 accumula-
tion and p21/WAF1 overexpression increased and a statistically
significant positive correlation between both factors could be
observed. This finding might be explained by a potentially
therapy-related up-regulation of functional (wild-type) p53
protein.
Paradoxically, all p21/WAF1-positive cases in our series
showed a high Ki-67 index and, occasionally, mitoses were also
p21/WAF1 immunoreactive (Figure 4). Our results are in accor-
dance with recent data from Trotter et al (1997) and from Erber et
al (1998) who were able to show an aberrant p21/WAF1 expres-
sion in human cutaneous melanomas and head and-neck squamous
cell carcinomas respectively. These data demonstrate that
increased p21 expression is not sufficient to control growth of
certain tumour entities in vivo. Moreover, Lukas et al (1997)
revealed tissue-specific expression patterns of p21/WAF1 in carci-
nomas of the breast, ovary and endometrium which appeared to
be characteristic of the tumour type. This finding suggests an
abnormal function of this important cell cycle inhibitor in a subset
of the tumour cells, resulting in a defective G1/S checkpoint
control and leading to an excessive tumour cell proliferation in
some human malignancies. Several molecular changes might
cause this escape from the regular cell cycle control, including (1)
mutations of the p21/WAF1 gene, (2) an alteration ‘downstream’
from the p53 and p21/WAF1-mediated G1/S checkpoint, or (3)
changes in other factors participating in the G1/S checkpoint
control (checkpoint adaptation, mutations of the CDKs or their
inhibitors).
To date, direct evidence for one of these hypotheses is lacking.
Nonetheless, PC was the first primary human cancer where
somatic mutations of the WAF1/CIP1 gene were detected. The
question of whether the mutated p21 protein is functional or non-
functional is still open. The rate of 17% of WAF1 gene mutations
in prostatic carcinomas reported by Gao et al (1995) is very similar
to the frequency of immunohistochemical p21/WAF1 protein
overexpression detected before ADT in the present study. Thus, it
might be speculated that WAF1 gene mutations could lead to a
mutated protein with abnormal stability. The abnormal protein –
either functional or non-functional – might become detectable by
immunohistochemistry in analogy to p53. Alternatively, the
binding of p21/WAF1 to the cyclin/CDK complexes might be
altered or inhibited by gene mutations. However, no data are as yet
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tions and p21/WAF1 protein overexpression. Recently,
Blagosklonny et al (1997) were able to show that the prostate
cancer cell line, LNCaP, became resistant to phorbol-12-myristate-
13-acetate (PMA)-induced growth arrest after transfection with
the c-myc oncogene, despite up-regulation of p21/WAF1. Thus,
continued c-myc expression obviously provided a circumvention
of growth inhibition by tumour suppressors. Furthermore, up-
regulation of cyclins might also bypass the p21-inhibitory effect
by altering binding stoichiometry (Trotter et al, 1997) and
p53-induced p21 WAF1 expression can mediate increased cyclin
D1 synthesis itself (Chen et al, 1995).
In conclusion, our results show that the physiologic regulation
of proliferation and apoptosis is defective in the majority of
advanced prostatic carcinomas already before ADT. The aberrant
expression of the cell cycle inhibitor p21/WAF1 in the tumour
cells before androgen withdrawal characterized a subgroup of
patients with unfavourable clinical course. This finding indicates
that the physiologic G1/S checkpoint of the cell cycle might be
impaired in these tumours. Further investigations will be neces-
sary to elucidate the causes for this failure on DNA and RNA
level. For the clinical practice, prospective investigations will have
to clarify whether the immunohistochemical demonstration of
p21/WAF1 overexpression in advanced prostate carcinomas can
be used as a marker for hormone-refractory high-risk tumours.
According to our results, these patients have no benefit from
conventional androgen deprivation therapy forms.
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